Table 3.
Clinical toxicity data in patients with CL treated in both groups
| Side effect symptoms (%) | Sbv + Pentoxifylline | CTC Grade | Sbv + Placebo | CTC Grade |
|---|---|---|---|---|
| Vomiting | 02 (2.4) | 2 (2)* | NR | NR |
| Diarrhea | 01 (1.2) | 2 (1) | NR | NR |
| Nausea | 07 (8.6) | 1 (5) | 02 (2.4) | 2 (2) |
| 2 (2) | ||||
| Headache | 09 (11) | 1 (4) | 05 (06) | 2 (3) |
| 2 (5) | 3 (2) | |||
| Asthenia | 03 (3.7) | 1 (1) | 02 (2.4) | 1 (1) |
| 2 (2) | 3 (1) | |||
| Anorexia | 03 (3.7) | 1 (1) | 01 (1.2) | 3 (1) |
| 2 (2) | ||||
| Epigastralgia | 03 (3.7) | 1 (2) | 02 (2.4) | 2 (1) |
| 2 (1) | 3 (1) | |||
| Pain | 02 (2.4) | 1 (1) | 02 (2.4) | 1 (2) |
| 2 (1) | ||||
| Dizziness | 02 (2.4) | 1 (2) | NR | NR |
| Fever | 06 (7.4) | 1 (3) | 02 (2.4) | 1 (1) |
| 2 (3) | 2 (1) | |||
| Arthralgia | 07 (8.6) | 1 (4) | 10 (12) | 1 (6) |
| 2 (3) | 2 (2) | |||
| 3 (2) | ||||
| Myalgia | 11 (13.5) | 1 (8) | 06 (7.3) | 1 (2) |
| 2 (2) | 2 (2) | |||
| 3 (1) | 3 (2) | |||
| Total | 31 (37.8) | 19 (23) |
CL = cutaneous leishmaniasis; CTC = common toxicity criteria; NR = not registered; Sbv = pentavalent antimony.
*
In parenthesis, the number absolute of patients for each CTC grade.